Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | TK2 | O00142 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Broxuridine SCHEMBL10316347 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL65484 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL14457631 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL27756 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL9153195 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL27755 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL20769775 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL21137660 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL21423028 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL5981680 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5416 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071273-A1 | METHODS FOR NUCLEIC ACID SEQUENCING | NANOHYB LLC (US) | 2026-03-12 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | claimed |
| US-12312631-B1 | High-throughput multiplexed sensitivity and resistance assay | SageMedic Corporation | 2025-05-27 | — | — | US | claimed |
| EP-4555317-A1 | A HIGH-THROUGHPUT MULTIPLEXED VIABILITY AND PROLIFERATION ASSAY | Sagemedic Corporation (US) | 2025-05-21 | — | — | EP | claimed |
| EP-4392076-A1 | SIRP-ALPHA ANTIBODIES AND CONJUGATES | Tallac Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| CN-118043078-A | SIRP-alpha antibodies and conjugates | 塔拉克治疗公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117836413-A | Connexin-4 antibodies and conjugates | 塔拉克治疗公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2023244699-A1 | A HIGH-THROUGHPUT MULTIPLEXED VIABILITY AND PROLIFERATION ASSAY | SageMedic Corporation (US) | 2023-12-21 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| EP-0712926-A2 | Fish pancreatic disease virus | Akzo Nobel N.V. (NL) | 1996-05-22 | — | — | EP | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| US-5470709-A | Gene mapping by hybridization to free chromatin | HSC RESEARCH & DEVELOPMENT LTD. PARTNERSHIP (CA) | 1995-11-28 | — | — | US | claimed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| EP-0306985-B1 | BACTERIORHODOPSIN MODIFICATIONS AND METHODS FOR THEIR PREPARATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1991-12-04 | — | — | EP | claimed |
| US-4816570-A | Biologically reversible phosphate and phosphonate protective groups | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-28 | — | — | US | claimed |
| EP-0306985-A2 | Bacteriorhodopsin modifications and methods for their preparation | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1989-03-15 | — | — | EP | claimed |
| EP-0175286-A2 | In vitro cell culture system and method | MCW Research Foundation, Inc. (US) | 1986-03-26 | — | — | EP | claimed |